Akorn PE Ratio 2006-2018 | AKRX

Current and historical p/e ratio for Akorn (AKRX) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Akorn PE ratio as of January 22, 2019 is 0.00.
Akorn PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-01-22 3.67 0.00
2018-09-30 12.98 $-1.26 0.00
2018-06-30 16.59 $-0.70 0.00
2018-03-31 18.71 $0.02 935.50
2017-12-31 32.23 $0.35 92.09
2017-09-30 33.19 $0.61 54.41
2017-06-30 33.54 $0.99 33.88
2017-03-31 24.08 $1.47 16.38
2016-12-31 21.83 $1.48 14.75
2016-09-30 27.26 $1.49 18.30
2016-06-30 28.49 $1.50 18.99
2016-03-31 23.53 $1.27 18.53
2015-12-31 37.31 $1.24 30.09
2015-09-30 28.51 $1.26 22.62
2015-06-30 43.66 $0.76 57.45
2015-03-31 47.51 $0.56 84.84
2014-12-31 36.20 $0.33 109.70
2014-09-30 36.27 $0.18 201.50
2014-06-30 33.25 $0.40 83.13
2014-03-31 22.00 $0.44 50.00
2013-12-31 24.62 $0.46 53.52
2013-09-30 19.68 $0.40 49.20
2013-06-30 13.52 $0.41 32.98
2013-03-31 13.83 $0.40 34.58
2012-12-31 13.36 $0.38 35.16
2012-09-30 13.22 $0.35 37.77
2012-06-30 15.77 $0.36 43.81
2012-03-31 11.70 $0.43 27.21
2011-12-31 11.12 $0.41 27.12
2011-09-30 7.80 $0.59 13.22
2011-06-30 7.00 $0.50 14.00
2011-03-31 5.77 $0.23 25.09
2010-12-31 6.07 $0.21 28.90
2010-09-30 4.04 $-0.05 0.00
2010-06-30 2.97 $-0.15 0.00
2010-03-31 1.53 $-0.13 0.00
2009-12-31 1.79 $-0.29 0.00
2009-09-30 1.37 $-0.28 0.00
2009-06-30 1.21 $-0.19 0.00
2009-03-31 0.86 $-0.14 0.00
2008-12-31 2.30 $-0.08 0.00
2008-09-30 5.13 $-0.12 0.00
2008-06-30 3.31 $-0.20 0.00
2008-03-31 4.73 $-0.22 0.00
2007-12-31 7.34 $-0.22 0.00
2007-09-30 7.49 $-0.23 0.00
2007-06-30 6.99 $-0.20 0.00
2007-03-31 6.75 $-0.18 0.00
2006-12-31 6.25 $-0.08 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.461B $0.841B
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies. Their strategy is focused on continuing to strengthen our leadership position in the development and marketing of specialized generic and branded pharmaceuticals, over-the-counter (`OTC`) drug products and animal health products.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.224B 9.14
Teva Pharmaceutical Industries (TEVA) Israel $19.066B 5.84
Mylan (MYL) United Kingdom $14.897B 6.13
Bausch Health Cos (BHC) Canada $8.016B 5.80
Dr Reddy's Laboratories (RDY) India $6.223B 24.82
Supernus Pharmaceuticals (SUPN) United States $1.966B 18.62
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.665B 2.78
Amphastar Pharmaceuticals (AMPH) United States $1.032B 111.95
Homology Medicines (FIXX) United States $0.866B 0.00
CymaBay Therapeutics (CBAY) United States $0.530B 0.00
Assembly Biosciences (ASMB) United States $0.521B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.404B 0.00
Voyager Therapeutics (VYGR) United States $0.267B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.237B 0.00
Sol-Gel Technologies (SLGL) Israel $0.110B 0.00
Teligent (TLGT) United States $0.097B 0.00
Acasti Pharma (ACST) Canada $0.086B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.066B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.056B 0.00
Evoke Pharma (EVOK) United States $0.049B 0.00
Agile Therapeutics (AGRX) United States $0.030B 0.00
Aevi Genomic Medicine (GNMX) United States $0.013B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.006B 0.00